14.88
-0.37(-2.43%)
Currency In USD
| Previous Close | 15.25 |
| Open | 15.05 |
| Day High | 15.17 |
| Day Low | 14.56 |
| 52-Week High | 25 |
| 52-Week Low | 6.36 |
| Volume | 1.72M |
| Average Volume | 2.46M |
| Market Cap | 2.41B |
| PE | -4.11 |
| EPS | -3.62 |
| Moving Average 50 Days | 18.46 |
| Moving Average 200 Days | 14.86 |
| Change | -0.37 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $622.59 as of February 22, 2026 at a share price of $14.88. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 5 years ago, it would be worth $756.1 as of February 22, 2026 at a share price of $14.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
GlobeNewswire Inc.
Jan 20, 2026 12:30 PM GMT
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational Expansion Cohort in early Q2 2026
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 12:30 PM GMT
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that Jo
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
GlobeNewswire Inc.
Dec 23, 2025 12:30 PM GMT
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the app